エピソード

  • Extensive-Stage Small Cell Lung Cancer — Current Patterns of Care with First-Line and Maintenance Therapy

    Extensive-Stage Small Cell Lung Cancer — Current Patterns of Care with First-Line and Maintenance Therapy
    2026/02/27

    Dr Hossein Borghaei from Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Dr Anne Chiang from Yale Cancer Center in New Haven, Connecticut, discuss key clinical trial data in the first-line management of ES-SCLC, real-world case studies and current patterns of care among oncologists.

    CME information and select publications here.
    続きを読む 一部表示
    1 時間
  • Extensive-Stage Small Cell Lung Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy

    Extensive-Stage Small Cell Lung Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy
    2025/12/17

    Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid and Dr Shields from Indiana University School of Medicine in Indianapolis discuss key datasets surrounding first-line and maintenance therapy for patients with extensive-stage small cell lung cancer and their clinical implications.

    CME information and select publications here.

    続きを読む 一部表示
    58 分
  • Lung Cancer — Proceedings from a Symposium Held in Partnership with the American Oncology Network

    Lung Cancer — Proceedings from a Symposium Held in Partnership with the American Oncology Network
    2025/12/12

    Dr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields summarize the treatment landscape and review relevant clinical datasets for patients with lung cancer.

    CME information and select publications here.

    続きを読む 一部表示
    1 時間 43 分
  • HER2-Altered Non-Small Cell Lung Cancer — An Interview with Dr John V Heymach

    HER2-Altered Non-Small Cell Lung Cancer — An Interview with Dr John V Heymach
    2025/12/10

    Dr John Heymach from The University of Texas MD Anderson Cancer Center in Houston discusses recent updates on available and novel treatment strategies for HER2-altered non-small cell lung cancer.

    CME information and select publications here.

    続きを読む 一部表示
    1 時間 5 分
  • Lung Cancer — 5-Minute Journal Club Issue 4 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

    Lung Cancer — 5-Minute Journal Club Issue 4 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
    2025/11/10

    Dr Aaron Lisberg from the University of California, Los Angeles, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer.

    CME information and select publications here.

    続きを読む 一部表示
    21 分
  • Lung Cancer — 5-Minute Journal Club Issue 3 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

    Lung Cancer — 5-Minute Journal Club Issue 3 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
    2025/10/20

    Dr Aaron Lisberg from the University of California, Los Angeles discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer.

    CME information and select publications here.

    続きを読む 一部表示
    25 分
  • Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 2 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

    Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 2 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
    2025/09/14

    Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of lung cancer.

    CME information and select publications here.

    続きを読む 一部表示
    23 分
  • Small Cell Lung Cancer — Expert Perspectives on Actual Patient Cases

    Small Cell Lung Cancer — Expert Perspectives on Actual Patient Cases
    2025/08/22

    Dr Stephen V Liu from Georgetown University Hospital in Washington, DC and Dr Charles Rudin from Memorial Sloan Kettering Cancer Center in New York discuss the role of approved and novel investigational therapies for patients with limited-stage and extensive-stage small cell lung cancer.

    CME information and select publications here.

    続きを読む 一部表示
    58 分